Accelerate Diagnostics Schedules Call to Review First Quarter 2017 Results for May 3rd
April 18 2017 - 5:53PM
Accelerate Diagnostics, Inc. announced today it will host a
conference call on Wednesday, May 3rd, 2017 to discuss its first
quarter 2017 financial results and commercial progress.
President and Chief Executive Officer, Lawrence Mehren, joined
by Steve Reichling, Chief Financial Officer, will review financial
results at 4:15 p.m. ET.
Conference Call
To participate in the conference call, dial +1.877.883.0383 and
enter the conference ID: 3295266.
International participants may dial +1.412.902.6506. Please dial
in 10-15 minutes prior to the start of the conference. A replay of
the call will be available by telephone at +1.877.344.7529 (U.S.)
or +1.412.317.0088 (international) using access code 10105794 until
May 17, 2017.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro
diagnostics company dedicated to providing solutions for the global
challenge of antibiotic resistance and healthcare-associated
infections. The company's Accelerate Pheno™ system and Accelerate
PhenoTest™ BC kit were recently cleared by the FDA for
antimicrobial susceptibility testing direct from positive blood
culture samples. The solution leverages proprietary molecular
identification methods and morphokinetic cellular analysis (MCA) to
provide minimum inhibitory concentrations for a range of applicable
antibiotics. The fully-automated system is designed to
eliminate the lengthy culture and sample preparation steps required
prior to antimicrobial susceptibility testing. Recent market
studies suggest the solution offers results 1-2 days faster than
conventional methods, enabling clinicians to optimize antibiotic
selection, dosage, and infusion strategy specific to the individual
patient and their infection.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and
“ACCELERATE PHENOTEST” logos and marks are trademarks or registered
trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products or
technology, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, about our projections as to
when certain key business milestones may be achieved, the potential
of our products or technology, the growth of the market, our
estimates as to the size of our market opportunity and potential
pricing, our competitive position and estimates of time reduction
to results, and our future development plans and growth strategy.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements.
Information about the risks and uncertainties faced
by Accelerate Diagnostics is contained in the section
captioned "Risk Factors" in the company's most recent Annual Report
on Form 10-K, filed with the Securities and Exchange
Commission on February 28, 2017, and in any other reports
that we file with the Securities and Exchange
Commission from time to time. The company's forward-looking
statements could be affected by general industry and market
conditions. Except as required by federal securities laws, the
company undertakes no obligation to update or revise these
forward-looking statements to reflect new events, uncertainties or
other contingencies.
Source: Accelerate Diagnostics, Inc.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100, investors@axdx.com
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100, achasteen@axdx.com
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024